Mpex was acquired by Axcan in 2011.
mtm was acquired by Roche for up to EUR190 million in 2011.
Nabriva was listed on NASDAQ in 2015.
Newron was listed on SIX Swiss Exchange in 2006.
Northstar was listed on NASDAQ in 2006.
ObsEva was listed on NASDAQ in 2017.
Ophthotech was listed on NASDAQ in 2013.
Panomics was acquired by Affymetrix for $73 million in 2008.
Paratek was listed on NASDAQ in 2014.
PharmaSwiss was acquired by Valeant for EUR350 million in 2009.
Precimed was acquired by GreatBatch for $125 million in 2008.
Principia was listed on NASDAQ in 2018, then acquired by Sanofi for $3.7 billion in 2020.
Probiodrug was listed on Euronext in 2014.
PTC was listed on NASDAQ in 2013.
Renovis was listed on NASDAQ in 2003.
Seer was listed on NASDAQ in 2020.
Secondary stake acquired by Creador Capital in 2020.
Merger with Vectura Group plc (LSE: VEC) in 2016.
Sloning was acquired by Morphosys in 2010.
Sunesis was listed on NASDAQ in 2005.
Symbiomix was acquired by Lupin for $150 million plus contingent payments in 2017.
Syntonix was acquired by Biogen Idec for up to $120 million in 2007.
Syrrx was acquired by Takeda for $270 million in 2005.
TandemLife was acquired by LivaNova (Nasdaq:LIVN) for up to $250 million in 2018.
Assets of Tensys were acquired by a Chinese Company by end of 2017.
Transform was acquired by Johnson & Johnson for $230 million in 2005.
True North Therapeutics was acquired by Bioverativ in 2017 for up to $825 million.
Turning Point was acquired by Bristol Myers Squibb for $4.1 billion in 2022.
Viela Bio was acquired by Horizon Therapeutics for $3 billion in 2021.
Vitaeris was acquired by CSL Behring in 2020.
Westmed was acquired by a subsidiary of Sunmed Group Holdings LLC for approximately $75 million in 2020.
Xenoport was listed on NASDAQ in 2005.
Sale of position to an investor in 2009.
Zycos was acquired by MGI Pharma for $50 million in 2004.